Outcome of patients with CML after SCT in the era of tyrosine kinase inhibitors

In this journal, Venepalli et al.1 reviewed the role of allo-SCT in CML in the era of tyrosine kinase inhibitors (TKIs). Unfortunately, due to the availability of first- and second-generation TKIs, allo-SCT is performed too late in most patients needing a transplant. Prognostic scores can be helpful in early identification of patients for whom allo-SCT is advantageous. However, one score was evaluated only retrospectively on data from 80 patients and therefore requires prospective validation.2 Landmark analyses of response parameters to nilotinib or dasatinib after imatinib resistance have been used to provisionally define patients with suboptimal response or resistance to second-line TKI therapy.3